Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that
has progressed after previous therapy. Safety and response to dasatinib will be assessed.
Fresh frozen tumor tissue must be available for genomics analysis prior to initiating
dasatinib therapy. A biopsy must be obtained after any prior chemotherapy. If fresh frozen
tumor tissue is not available, a biopsy will be required to participate in this trial.